

**Attorney Docket** : **ANVIL.001BNP1**  
**Appl. No.** : **10/584,968**  
**Filed** : **June 30, 2006**

### **AMENDMENTS TO THE CLAIMS**

1.-13. **(Canceled)**

14. **(Original)** A prosthesis for placement at an opening from a main body lumen to a branch body lumen, the prosthesis comprising:

at least one radially expansible support, the support configured to be deployed in at least a portion of the branch body lumen;

at least one frond extending from an end of the support and configured to be positioned across the Os and into the main body lumen; and

at least one circumferential link connected to the frond, the circumferential link spaced axially apart from the support.

15. **(Original)** The prosthesis as in Claim 14, wherein the circumferential link is expandable from a first, reduced diameter to a second, enlarged diameter.

16. **(Original)** The prosthesis as in Claim 14, wherein the at least one frond includes at least three fronds.

17. **(Original)** The prosthesis as in Claim 14, wherein the at least one frond comprises a helical configuration.

18. **(Original)** The prosthesis as in Claim 17, comprising a plurality of helical fronds.

19. **(Original)** The prosthesis as in Claim 14, wherein at least a portion of the frond comprises a lubricous coating.

20. **(Original)** The prosthesis as in Claim 14, wherein the support is on a first end of the frond, and the circumferential link is on a second end of the frond.

21. **(Original)** The prosthesis as in Claim 14, wherein the circumferential link is radiopaque.

Attorney Docket : ANVIL.001BNP1  
Appl. No. : 10/584,968  
Filed : June 30, 2006

22. (Original) The prosthesis as in Claim 21, wherein the circumferential link has a greater radiopacity than the frond.

23. (Original) The prosthesis as in Claim 14, comprising an endothelial cell ingrowth surface.

24. (Original) The prosthesis as in Claim 14, comprising a non thrombogenic surface.

25.-29. (Canceled)

30. (Currently Amended) The prosthesis as in Claim 14, wherein the ~~plurality of fronds~~ at least one frond includes at least three fronds.

31. (Currently Amended) The prosthesis as in Claim 14, wherein the ~~plurality of fronds~~ at least one frond comprises a helical configuration.

32. (Previously Presented) The prosthesis as in Claim 31, comprising a plurality of helical fronds.

33. (Currently Amended) The prosthesis as in Claim 14, wherein at least a portion of the ~~plurality of fronds~~ at least one frond comprises a lubricous coating.

34. (Previously Presented) The prosthesis as in Claim 14, comprising an endothelial cell ingrowth surface.

35. (Previously Presented) The prosthesis as in Claim 14, comprising a non thrombogenic surface.

36. (Currently Amended) The prosthesis as in Claim 14, wherein the at least one frond comprises a plurality of fronds and wherein the ~~further comprising a circumferential link that connects to~~ each of the plurality of fronds.

**Attorney Docket** : **ANVIL.001BNP1**  
**Appl. No.** : **10/584,968**  
**Filed** : **June 30, 2006**

37. **(Previously Presented)** The prosthesis as in Claim 36, wherein at least a portion of the radially expansible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

38. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

39. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is one of an anti-cell proliferative, anti cell migration, anti-neo plastic, anti inflammatory drug.

40. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is configured to reduce an incidence or amount of restenosis.

41. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating includes a first coating and a second coating.

42. **(Previously Presented)** The prosthesis as in Claim 41, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

43. **(Previously Presented)** The prosthesis as in Claim 36, wherein the circumferential link is expandable from a first, reduced diameter to a second, enlarged diameter.

44. **(Previously Presented)** The prosthesis as in Claim 36, wherein the support is on a first end of at least one of the fronds, and the circumferential link is on a second end of at least one of the fronds.

45. **(Currently Amended)** The prosthesis as in Claim ~~[[36]]~~14, wherein the circumferential link is radiopaque.

**Attorney Docket** : **ANVIL.001BNP1**  
**Appl. No.** : **10/584,968**  
**Filed** : **June 30, 2006**

46. **(Currently Amended)** The prosthesis as in Claim ~~[[36]]~~14, wherein the circumferential link has a greater radiopacity than the at least one frond.

47. **(New)** The prosthesis of Claim 14, wherein the prosthesis includes a drug incorporated into a polymer matrix.

48. **(New)** The prosthesis of Claim 14, wherein the prosthesis includes a laminate structure and a drug incorporated into the laminate structure.

49. **(New)** The prosthesis of Claim 48, wherein the laminate structure includes a base layer and a top layer, the drug being incorporated into at least one of the top layer and the base layer.

50. **(New)** The prosthesis of Claim 14, wherein the prosthesis includes one or more reservoirs configured to be loaded with a drug.

51. **(New)** The prosthesis of Claim 50, wherein the prosthesis includes one or more drugs in the one or more reservoirs.